Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Aminopyridines for the treatment of neurologic disorders.

Strupp M, Teufel J, Zwergal A, Schniepp R, Khodakhah K, Feil K.

Neurol Clin Pract. 2017 Feb;7(1):65-76. doi: 10.1212/CPJ.0000000000000321. Review.

PMID:
28243504
2.

Dalfampridine effects on cognition, fatigue, and dexterity.

Korsen M, Kunz R, Schminke U, Runge U, Kohlmann T, Dressel A.

Brain Behav. 2016 Nov 11;7(1):e00559. doi: 10.1002/brb3.559.

3.

Fatigue Management in Multiple Sclerosis.

Tur C.

Curr Treat Options Neurol. 2016 Jun;18(6):26. doi: 10.1007/s11940-016-0411-8. Review.

4.

Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).

Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U, Oschmann P, Muenssinger J.

BMC Neurol. 2015 Sep 24;15:171. doi: 10.1186/s12883-015-0431-0.

5.

Difference in Motor Fatigue between Patients with Stroke and Patients with Multiple Sclerosis: A Pilot Study.

Sehle A, Vieten M, M√ľndermann A, Dettmers C.

Front Neurol. 2014 Dec 22;5:279. doi: 10.3389/fneur.2014.00279.

6.
7.

Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis.

Prosperini L, Giannì C, Fortuna D, Marchetti MR, Pozzilli C.

Mult Scler Int. 2014;2014:802307. doi: 10.1155/2014/802307.

8.

4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Jensen HB, Ravnborg M, Dalgas U, Stenager E.

Ther Adv Neurol Disord. 2014 Mar;7(2):97-113. doi: 10.1177/1756285613512712. Review.

9.

Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D.

Neurology. 2013 Nov 19;81(21):1856-63. doi: 10.1212/01.wnl.0000436065.97642.d2.

10.

Targeting ion channels for the treatment of autoimmune neuroinflammation.

Bittner S, Meuth SG.

Ther Adv Neurol Disord. 2013 Sep;6(5):322-36. doi: 10.1177/1756285613487782.

11.

Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.

Rabadi MH, Kreymborg K, Vincent AS.

Drugs R D. 2013 Sep;13(3):175-81. doi: 10.1007/s40268-013-0020-x.

12.

Dalfampridine: review of its efficacy in improving gait in patients with multiple sclerosis.

Sahraian MA, Maghzi AH, Etemadifar M, Minagar A.

J Cent Nerv Syst Dis. 2011 May 16;3:87-93. doi: 10.4137/JCNSD.S4868.

13.

Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy).

Goodman AD, Stone RT.

Neurotherapeutics. 2013 Jan;10(1):106-10. doi: 10.1007/s13311-012-0156-3. Review.

14.

Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment.

Hersh C, Rae-Grant A.

Ther Adv Neurol Disord. 2012 Jul;5(4):199-204. doi: 10.1177/1756285612447091.

15.

4-aminopyridine toxicity: a case report and review of the literature.

King AM, Menke NB, Katz KD, Pizon AF.

J Med Toxicol. 2012 Sep;8(3):314-21. doi: 10.1007/s13181-012-0248-9. Review.

16.

A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias.

Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, Freilinger T, Neugebauer H, Spiegel R, Dichgans M, Lehmann-Horn F, Jurkat-Rott K, Brandt T, Jen JC, Jahn K.

Neurology. 2011 Jul 19;77(3):269-75. doi: 10.1212/WNL.0b013e318225ab07.

17.

Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

de Sa JC, Airas L, Bartholome E, Grigoriadis N, Mattle H, Oreja-Guevara C, O'Riordan J, Sellebjerg F, Stankoff B, Vass K, Walczak A, Wiendl H, Kieseier BC.

Ther Adv Neurol Disord. 2011 May;4(3):139-68. doi: 10.1177/1756285611403646.

18.

Treatment of walking impairment in multiple sclerosis with dalfampridine.

Blight AR.

Ther Adv Neurol Disord. 2011 Mar;4(2):99-109. doi: 10.1177/1756285611403960.

19.

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.

Hayes KC.

Neuropsychiatr Dis Treat. 2011;7:229-39. doi: 10.2147/NDT.S10469.

20.

New approaches in the management of multiple sclerosis.

Barten LJ, Allington DR, Procacci KA, Rivey MP.

Drug Des Devel Ther. 2010 Nov 24;4:343-66. doi: 10.2147/DDDT.S9331. Review.

Supplemental Content

Support Center